lncRNA UCA1 Is a Novel Regulator in Cardiomyocyte Hypertrophy through Targeting the miR-184/HOXA9 Axis

Abstract

Cardiac hypertrophy is closely associated with a series of cardiovascular diseases, including heart failure and sudden death in particular. An in-depth comprehension of the pathogenesis of cardiac hypertrophy will improve the diagnosis and therapy of cardiac hypertrophy. It has been acknowledged that long noncoding RNAs/microRNAs (lncRNAs/miRNAs) are crucial regulators in diverse biological processes, including various cardiovascular diseases, in multiple manners. Nevertheless, the biological roles of lncRNA UCA1 and miR-184 in cardiac hypertrophy are scarcely reported. In this paper, qRT-PCR analysis exhibited that lncRNA UCA1 was highly expressed in mice heart treated with transverse aortic constriction (TAC) and the cardiomyocytes treated with phenylephrine (PE). On the contrary, miR-184 was downregulated under the same conditions. In addition, it was deduced that lncRNA UCA1 was reversely related with miR-184 in PE-triggered hypertrophic cardiomyocytes, confirmed by the Spearman correlation analysis. The knockdown of UCA1 or the overexpression of miR-184 lessened the enlarged surface area of cardiomyocytes and the elevated expressions of fetal genes (ANP and BNP) induced by PE. Later, it was determined that miR-184 was a direct target of UCA1, whereas the mRNA HOXA9 was a target of miR-184. Rescue assays indicated that UCA1 promoted the progression of cardiac hypertrophy through competitively binding with miR-184 to enhance the expression of HOXA9.

The long noncoding RNA XIST regulates cardiac hypertrophy by targeting miR‐101

“…The heart‐specific lncRNA Chaer was reported to interact with PRC2, contributing to the activation of pathological cardiac hypertrophy genes (Wang et al, ). lncRNA UCA1 was confirmed to be an activator in cardiomyocyte hypertrophy responses via modulating miR‐184 (G. Zhou, Li, Feng, Zhang, & Fang, ). lncRNA XIST is located on the X chromosome in the X‐inactivation center (Brockdorff et al, ).…”

LncRNA SNHG1 exerts a protective role in cardiomyocytes hypertrophy via targeting miR‐15a‐5p/HMGA1 axis

“…Recently, miR‐15a‐5p is found to be upregulated in plasma of hypertrophic cardiomyopathy patients (Fang et al, 2015). Simvastatin attenuates cardiomyocytes apoptosis by inhibiting miR‐15a‐5p and then increasing Bcl‐2 (Zhou et al, 2018a,b). These evidences suggest that miR‐15a‐5p might be a crucial regulator to mediate cardiac functions.…”

Potential regulatory network in the PSG10P/miR‐19a‐3p/IL1RAP pathway is possibly involved in preeclampsia pathogenesis

“…Bioinformatic analysis revealed that PSG10P can promote the expression of IL1RAP by sponging miR‐19a‐3p. Many studies have been performed on the interactions among RNA molecules, such as interactions between lncRNA‐miRNA and miRNA‐mRNA . Here, we focused on the interaction between PSG10P‐miR‐19a‐3p and miR‐19a‐3p‐ IL1RAP .…”

“…Many studies have been performed on the interactions among RNA molecules, such as interactions between lncRNA-miRNA and miRNA-mRNA. 24,25 Here, we focused on the interaction between PSG10P-miR-19a-3p and miR-19a-3p-IL1RAP. In addition, we hypothesized that the PSG10P/ miR-19a-3p/IL1RAP network regulates the growth and invasion of trophoblastic cells under hypoxia.…”